MOV纳米粒的构建及其通过恢复气道免疫调节功能改善气道过敏性疾病的作用OA

Objective To construct a nanoparticle-based carrier capable of restoring airway immunoregulatory function under allergic conditions,and evaluate its immunomodulatory effects and potential therapeutic value against allergic airway inflammation.Methods Vasoactive intestinal peptide(VIP)-loaded nanoparticles(VIP NPs)were prepared using a double-emulsion method and further modified with an MHC-Ⅱ/OVA epitope peptide fusion protein to generate MOV nanoparticles(MOV NPs).The physicochemical properties and in vitro release profile of MOV NPs were characterized.An ovalbumin(OVA)-induced murine model of allergic airway disease was established and treated with different doses of MOV NPs.Serum allergen-specific antibodies,inflammatory mediators and Th2 cytokines in bronchoalveolar lavage fluid(BALF)were measured.Flow cytometry and functional assays were performed to analyze the abundance and suppressive activity of regulatory T cells(Tregs)in airway tissues.The expression levels of Treg-associated cytokines,transforming growth factor-β(TGF-β)and interleukin-10(IL-10)were further determined.Results MOV NPs exhibited a uniform spherical morphology,negative surface charge,stable sustained-release properties,and a VIP encapsulation efficiency of(63.12±2.15)%.MOV NPs treatment significantly reduced serum sIgG1 and sIgE levels,as well as BALF inflammatory mediators and Th2 type cytokines,in a dose-dependent manner.Compared with the model group,MOV NPs markedly increased the number and immunosuppressive function of airway Tregs,and up-regulated the expression levels of TGF-β and IL-10.Conclusion MOV NPs integrate dual functions of antigen presentation and VIP-mediated immunoregulation,which can effectively inhibit airway allergic inflammation and restore local immune homeostasis.